Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151984 | 0.83 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3HTR2AMAPT | |
| SCHEMBL18313564 | 0.82 | AR (0.51) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| SCHEMBL1046654 | 0.82 | MAPT (0.48) | SLC6A4SLC6A2SLC6A3ARGRIN2B | |
| SCHEMBL5542724 | 0.81 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| SCHEMBL327806 | 0.80 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| SCHEMBL5023464 | 0.79 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| SCHEMBL5024669 | 0.79 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| Hydrogen Sulfide SCHEMBL28150140 | 0.78 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| SCHEMBL22167231 | 0.77 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3ARRIPK1 | |
| SCHEMBL29552882 | 0.77 | HRH1 (0.53) | SLC6A4SLC6A2SLC6A3ARRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SLC6A4 4191/4885SLC6A2 3396/4885SLC6A3 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.